To include your compound in the COVID-19 Resource Center, submit it here.

RPC1063: Phase II data

Additional data from 258 patients with relapsing MS in the Phase II portion of the double-blind, international Phase II/III RADIANCE trial showed that once-daily oral RPC1063 reduced the number of gadolinium-enhancing lesions at week 24, a secondary endpoint, by 91% at the 0.5 mg dose

Read the full 457 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE